Form 483

ECI Pharmaceuticals LLC Form 483, 2016-11-18

FDA issued a Form 483 to ECI Pharmaceuticals LLC on 2016-11-18 with 24 public-safe observations.

483· Form 483 issuedHuman Drugs24 observations

ECI Pharmaceuticals LLC · Ft Lauderdale, United States · Issued November 18, 2016

Overview

  • 24 public-safe observations are available for this inspection.
  • 6 structured CFR citations are represented.
  • 2 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

18 Nov 2016
21 CFR 211.110(a)(3)

Mixing adequacy

Cited by Jennifer Lalama, Ileana Barreto-Pettit

18 Nov 2016
21 CFR 211.110(a)(3)

Mixing adequacy

Cited by Jennifer Lalama, Ileana Barreto-Pettit

18 Nov 2016
21 CFR 211.110(a)(3)

Mixing adequacy

Cited by Jennifer Lalama, Ileana Barreto-Pettit

18 Nov 2016
21 CFR 211.160(a)

Following/documenting laboratory controls

Cited by Jennifer Lalama, Ileana Barreto-Pettit

18 Nov 2016
21 CFR 211.160(a)

Following/documenting laboratory controls

Cited by Jennifer Lalama, Ileana Barreto-Pettit

Inspected site

EPECI Pharmaceuticals LLCFt Lauderdale, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.110(a)(3)Cited across public-safe Form 483 observations4x
21 CFR 211.160(a)Cited across public-safe Form 483 observations4x
21 CFR 211.42(c)Cited across public-safe Form 483 observations4x
21 CFR 211.46(b)Cited across public-safe Form 483 observations4x
21 CFR 211.63Cited across public-safe Form 483 observations4x
21 CFR 211.67(b)Cited across public-safe Form 483 observations4x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 24 observations

The source PDF and every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere